X Li, C Wang, S Li, F Yin, H Luo, Y Zhang, Z Luo… - European journal of …, 2023 - Elsevier
Currently available PARP inhibitors are mainly used for the treatment of BRCA-mutated
triple-negative breast cancer (TNBC), with a narrow application range of approximately 15 …